Expression and prognostic roles of the G1-S modulators in hepatocellular carcinoma: p27 Independently predicts the recurrence

Hepatology

Volumn 30, Issue 1, 1999, Pages 90-99

  Ito, Yasuhiro ^a   Matsuura, Nariaki ^a,b   Sakon, Masato ^a   Miyoshi, Eiji ^c   Noda, Katsuhisa ^c   Takeoa, Tsutomu ^a   Umeshita, Koji ^a   Nagano, Hlroyukl ^a   Nakamori, Shoji ^a   Dono, Keizo ^a   Tsujimoto, Masahiko ^b   Nakahara, Masaaki ^c   Nakao, Kazuyasu ^c   Taniguchi, Naoyuki ^c   Monden, Morito ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c OSAKA POLICE HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYCLIN E; GENE PRODUCT; PROTEIN P16; PROTEIN P21; PROTEIN P27; PROTEIN P53;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GROWTH; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECURRENT DISEASE; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL CYCLE PROTEINS; CYCLIN D1; CYCLIN E; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLINS; FEMALE; FOLLOW-UP STUDIES; G1 PHASE; GENES, RETINOBLASTOMA; HUMANS; LIVER NEOPLASMS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECURRENCE; RETINOBLASTOMA PROTEIN; S PHASE; SURVIVAL ANALYSIS; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 0032995914     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510300114     Document Type: Article

References (29)

1. 1 events and regulation of cell proliferation. Science 1989;246:603-608.
2. Friend SH, Bernards R, Rogelj S, Weinberg RA, Rapaport JM, Albert DM, Dryjia TR A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 1986;323:643-646.
3. Chellappan SP, Hiebert S, Mudryj M, Horowitz JM, Nevens JR. The E2F transcription factor is a cellular target for the RB protein.Cell 1991;65: 1053-1061.
4. Lees JA, Buchkovich KJ, Marshak DR, Anderson CW, Harlow E. The retinoblastoma protein is phosphorylated on multiple sites by human cdc2. EMBO J 1991;10:4279-4290.
5. Mittnacht S, Lees JA, Desai D, Harlow E, Morgan DO, Weinberg RA. Distinct sub-populations of the retinoblastoma protein show a distinct pattern of phosphorylation. EMBO J 1994;13:118-127.
6. Motokura T, Bloom T, Kim HG, Juppner H, Ruderman JV, Kronenbereg HM, Arnold A. A novel cyclin encoded by a bell-linked candidate oncogene. Nature 1991;350:512-515.
7. Motokura T, Keyomarsi K, Kronenberg HM, Arnold A. Cloning and characterization of human cyclin D3, a cDNA closely related in sequence to the PRADl/cyclin D1 proto-oncogene. J Biol Chem 1992;267:20412-20415.
8. Quelle DE, Ashmun RA. Shurtleff SA, Kalo JY, Bar-Sagi D, Roussel MF, Sherr CJ. Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. Genes Dev 1993;7:1559-1571.
9. Matsushime H, Ewen ME, Strom DK, Kato JY, Hanks SK, Roussel MF, Sherr CJ. Identification and properties of an atypical catalytic subunit (p34PSK-J3/cdk4) for mammalian D type Gl cyclins. Cell 1992;71:323-334.
10. Koff A, Cross F, Fisher A, Schumacher J, Leguellec K, Philippe M, Roberts JM. Human cyclin E, a new cyclin that intereacts with two members of the CDC2 gene family. Cell 1991;66:1217-1228.
11. Koff A, Giordano A, Desai D, Yamashita K, Harper JW, Elledge S, Nishimoto T, et al. Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle. Science 1992;257:1689-1694.
12. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993;366: 705-707.
13. Mori T, Miura K, Aoki T, Nishihara T, Mori S, Nakamura Y. Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/ cyclin dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res 1994;54:3396-3397.
14. Caldas C, Hahn SA, da Costa LT, Redston MS, Shibata A, Simoneau AR, Lin MF, et al. p16 mutation in uncultured tumours. Nature 1994;370:183-184.
15. Kees DR, Ranford PR, Hatzis M. Deletions of the p16 gene in pediatric leukemia and corresponding cell lines. Oncogene 1996;12:2235-2239.
16. Zhou X, Tarmin L, Tin J, Jiang HY, Suzuki H, Rhyu MG, Abraham JM. The MTS1 gene is frequently mutated in primary human esophageal tumors. Oncogene 1994;9:3737-3741.
17. Merlo A, Herman JG, Mao L, Gabrielson E, Burger PC, Baylin SB, Sideransky D. 5' CpG island methylation is associated with transcriptional silencing of the tumor suppressor pl6/CDKN2/MTS1 in human cancers. Nat Med 1995;l:686-692.
18. Lukas J, Parry D, Agaard L. Retinoblastoma protein dependent cell-cycle inhibition by the tumor suppressor p16. Nature 1995;375:503-505.
19. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993;366:701-704.
20. Waga S, Hannon GJ, Beach D, Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 1994;371:534-537.
21. El-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, Pietenopol JA, et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 1994;54:1169-1174.
22. El Deiry WS, Tokino T, Velculescu VE, Levy DB, Parson R, Trent JM, Lin D. WAF1, a potent inhibitor of p53 tumor suppression. Cell 1993;75:817-825.
23. Michiell P, Chedid M, Lin D, Pierce JH, Mercer WE, Givol D. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res 1994;54:3391-3395.
24. Ikeguchi M, Saito H, Katano K, Tsujitani S, Maeta M, Taibara N. Expression of p53 and p21 are independent prognostic factors in patients with serosal invasion by gastric carcinoma. Dig Des Sci 1998;43:964-970.
25. Ito K, Sasano H, Matsunaga G, Ssato S, Yajima A, Nasim S, Garret CT. Correlations between p21 expression and clinicopathological findings, p53 gene and protein alterations, and survival in patients with endometrial carcinoma. J Pathol 1997;183:318-324.
26. Shiohara M, El-Deiry WS, Wada M, Nakamaki T, Takeuchi S, Yang R, Chen DL, et al. Absence of WAF1 mutations in a variety of human malignancies. Blood 1994;84:3781-3784.
27. KIP1, a cyclin-dependem kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994;78: 59-66.
28. Kipl) of cyclin-dependent kinase 4 activity. Cell 1994;79:487-496.
29. Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 1994;372: 570-573.